Moneycontrol
HomeNewsBusinessCompaniesL&T says it will take few more quarters for normalcy in business operations to return

L&T says it will take few more quarters for normalcy in business operations to return

The company said it had lost about Rs 12,500 crores in revenue in Q1FY21 and declined to give guidance on order book, EBITDA and revenue citing uncertainity.

July 22, 2020 / 21:42 IST
Story continues below Advertisement

Larsen & Toubro (L&T), India's largest engineering and construction company, said the revenue ramp-up would be gradual, and it will take a few more quarters for the company to get anywhere close to normalcy.

The company said it had lost about Rs 12,500 crores in revenue in Q1FY21 and declined to give guidance on the order book, EBITDA and revenue citing uncertainty.

Story continues below Advertisement

"It's still too early to give guidance because we still don't know what is going to happen," said S N Subrahmanyan, Chief Executive Officer (CEO) and Managing Director of L&T said in a post-earnings media call.

L&T net profit slumped 79 percent year-on-year to Rs 303 crore as compared to Rs 1,473 crore for the corresponding quarter of the previous year. The Profit After Tax (PAT) was impacted mainly due to lower revenue, credit provisions in the financial services businesses, and under recoveries. 

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show